Megafil

Quick links to important sections

Megafil

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Megafil

Quick Facts

Property Description
Active ingredient Tadalafil (INN)
Form Film-coated tablets
Pharmacological class Phosphodiesterase type 5 (PDE5) inhibitor
General purpose Enhances circulatory response in targeted tissues
Origin Synthetic compound

Megafil: Identity, Composition, and Pharmacological Class

Megafil is a synthetic, single-ingredient oral medication defined by its active entity, Tadalafil (INN). This compound is classified as a Phosphodiesterase type 5 (PDE5) inhibitor, a drug class used to modulate specific physiological responses. Tadalafil is a Pyrido[3,4-b]pyrazine compound with the empirical formula C22H19N3O4 and is produced through chemical synthesis.

The medication is supplied as a film-coated tablet intended for oral administration, consisting of the active Tadalafil embedded within an inert solid excipient matrix. Tadalafil functions as a selective inhibitor, meaning its primary mechanism is to block the PDE5 enzyme, a protein involved in regulating specific blood flow mechanisms. This selective action is designed to enhance the effects of naturally occurring signaling molecules in the body.

Function and General Therapeutic Purpose

The foundational purpose of Megafil is connected to its pharmacological action, which facilitates smooth muscle relaxation within specific blood vessel walls. This leads to increased localized blood flow, supporting the body's response to circulatory signals. Tadalafil is characterized by a prolonged half-life compared to other PDE5 inhibitors, providing a persistent physiological presence and a broad window of effect. The general therapeutic utility of Megafil is to facilitate natural mechanisms in instances where enhanced blood delivery is required for physiological function.

What side effects are possible with Megafil?

Possible Side Effects and Safety Information

The following information summarizes the officially documented adverse reactions and safety constraints for Megafil (tadalafil), as published in governmental regulatory documents. This section does not include guidance on use or therapeutic benefits.

Adverse Reaction Classification

Classification Common Side Effects (Reported in ge 2% of studies) System-Organ Classes Affected
Frequency Headache, dyspepsia (indigestion), back pain, myalgia (muscle aches), nasal congestion, flushing, pain in limb. Nervous System, Gastrointestinal, Musculoskeletal, Vascular, Eye, Ear/Labyrinth.

Certain common adverse reactions, such as headache, dyspepsia, and muscle pain, are explicitly noted in regulatory documents as being more common at higher doses.

Serious and Clinically Significant Adverse Reactions

Regulatory sources document rare, but serious, adverse reactions that have been reported, primarily post-marketing. These include:

  • Non-arteritic Anterior Ischemic Optic Neuropathy (NAION): A condition involving sudden decrease or loss of vision, which may be permanent.
  • Priapism: A prolonged, painful erection lasting four hours or longer. Untreated priapism can cause permanent damage.
  • Sudden Hearing Loss: Sudden decrease or loss of hearing, sometimes accompanied by tinnitus (ringing in the ears).
  • Serious Cardiovascular Events: Events such as myocardial infarction, stroke, and ventricular arrhythmia have been reported.

Safety Constraints and Limitations

Official labeling includes specific restrictions on the use of Megafil:

  • Absolute Contraindication: Megafil is strictly contraindicated for use with any form of organic nitrates or with guanylate cyclase (GC) stimulators due to the risk of severe and dangerous hypotension.
  • Hepatic and Renal Impairment: Use is not recommended in patients with severe hepatic impairment (Child-Pugh Class C) or in patients with severe renal impairment (creatinine clearance <30 mL/min).
  • Other Conditions: Caution is advised for patients predisposed to priapism (e.g., sickle cell anemia, multiple myeloma, leukemia) or those with anatomical deformation of the penis.

This regulatory safety structure emphasizes both the common, transient effects and the necessity of adhering to the documented constraints, particularly concerning drug interactions and specific pre-existing health conditions.

Overdose and Emergency Response

Overdose Manifestations

If a dose of Megafil (Tadalafil) exceeding the prescribed amount is taken, the officially documented clinical manifestations are generally expected to be similar to the typical adverse effects, potentially occurring with greater intensity. These signs, listed in regulatory documentation, may include headache, myalgia (muscle aches), dyspepsia (indigestion), back pain, and dizziness.

When to Seek Immediate Medical Help

Regulatory authorities mandate that emergency medical attention must be sought immediately for specific severe outcomes linked to Megafil exposure. The most critical instruction is to seek immediate treatment if an erection lasts longer than four hours (priapism), as this condition carries the official risk of permanent loss of potency if not addressed rapidly. Additionally, patients are instructed to stop use and seek prompt medical attention if they experience sudden loss of vision or a sudden decrease or loss of hearing.

Officially Described Management and Exposure Risk

The required management for overdose is symptomatic and supportive treatment. Regulatory documents confirm that no specific antidote is known for Tadalafil, and standard procedures like hemodialysis contribute negligibly to its elimination. Regulatory warnings also note that patients with severe renal or hepatic impairment face a significantly increased risk of drug exposure, which is a key population-specific consideration for overdose management.

Therapeutic Uses of Megafil

What Megafil Treats: Main Uses and Benefits

Megafil (Tadalafil) is commonly used across several major therapeutic domains, providing supportive relief and helping patients cope with significant symptomatic manifestations related to organ-specific functional stress. The medication is generally used to address Erectile Dysfunction (ED), Lower Urinary Tract Symptoms (LUTS) associated with Benign Prostatic Hyperplasia (BPH), and to assist in the management of Pulmonary Arterial Hypertension (PAH). The medication is relevant for conditions presenting with systemic or localized discomfort.

In various applications, Megafil assists with managing symptoms related to localized physical discomfort, helping to maintain rigidity for men with ED. It is relevant in contexts involving heightened systemic burden, which contributes to greater spontaneity and improved day-to-day comfort. Regarding BPH, the medication is applied when patients experience bothersome urinary symptoms that interfere with daily comfort, such as the frequent need to urinate or a weak stream. This provides support that helps ease the overall symptom burden. For PAH, the supportive therapy is relevant in managing symptoms like shortness of breath and fatigue.


Quick Facts: Relief for Functional Strain

The medication is commonly used in conditions presenting with recurrent or episodic manifestations where symptoms create noticeable functional strain. It assists with managing symptom clusters that may become intense or disruptive, contributing to improved comfort during symptomatic periods.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Who Can and Cannot Use Megafil?

Eligibility for Megafil (Tadalafil) is defined strictly by official regulatory documents, primarily centered on patient health status and co-existing medications.

Absolute Contraindications

The medicine is contraindicated and must not be used by patients taking any form of organic nitrate (e.g., nitroglycerin) or Guanylate Cyclase (GC) Stimulators (e.g., riociguat), due to the risk of severe blood pressure drops. Use is also contraindicated in individuals with a known hypersensitivity to tadalafil or excipients, and in patients for whom sexual activity is inadvisable due to their cardiovascular status.

Population and Comorbidity Restrictions

Population Group Regulatory Status
Pediatric Population Use is not indicated as safety and efficacy have not been established for ED/BPH indications.
Severe Renal/Hepatic Impairment Not recommended due to increased exposure risk and limited clinical data. Use in moderate impairment requires caution.
Recent Cardiovascular Event Contraindicated in those with a history of myocardial infarction within the last 90 days or stroke within the last six months.
Pregnancy and Lactation Not recommended due to insufficient safety data in women; caution is advised during breastfeeding.

Use requires caution in patients predisposed to priapism (e.g., sickle cell disease) or those with certain hereditary retinal disorders.

What should I know about interactions with other medicines?

Megafil Interactions with other medicines and products

Official regulatory information for Megafil (Tadalafil) defines several clinically significant drug and substance interactions.

Contraindicated Combinations

The co-administration of Megafil is contraindicated with certain medicinal products due to the risk of severe pharmacodynamic interaction. This includes all forms of Organic Nitrates (e.g., Nitroglycerin, Isosorbide Dinitrate) and Guanylate Cyclase (GC) Stimulators (e.g., Riociguat). The combination of Megafil with any organic nitrate is prohibited for at least 48 hours following the last Megafil dose.

Metabolic and Exposure Interactions

Megafil is predominantly cleared by the liver enzyme Cytochrome P450 3A4 (CYP3A4). Substances that interfere with this enzyme can alter Megafil exposure:

  • Potent CYP3A4 Inhibitors (e.g., Ketoconazole, Ritonavir) increase Megafil plasma levels (AUC).
  • Potent CYP3A4 Inducers (e.g., Rifampicin/Rifampin) decrease Megafil exposure, potentially reducing efficacy.

Pharmacodynamic and Additive Risks

Megafil can potentiate the effects of other blood pressure-lowering agents. Concomitant use with Alpha-Blockers (e.g., Doxazosin) and other Antihypertensive Medicinal Products carries an additive risk of symptomatic hypotension. The combination of Megafil with the alpha-blocker Doxazosin is officially not recommended.

Substance and Population Notes

Substantial consumption of alcohol (ge 5 units) may increase the potential for orthostatic signs and symptoms. Use of Megafil is generally avoided in patients with severe renal impairment or severe hepatic impairment due to increased exposure or insufficient clinical data, respectively.

Mechanism of Action

How Megafil Works

Megafil (Tadalafil) acts by precisely intervening in the natural signaling cascade that regulates smooth muscle tone in specific vascular beds. The primary mechanism is the selective competitive inhibition of the enzyme Phosphodiesterase type 5 (PDE5). This enzyme is responsible for the hydrolysis of the key second messenger molecule, cyclic Guanosine Monophosphate (cGMP).

By blocking PDE5, Megafil prevents the breakdown of cGMP, thereby ensuring the maintenance of elevated cGMP levels within the targeted smooth muscle cells. This action is entirely dependent on the prior release of the natural vasodilator signal, Nitric Oxide (NO), which initiates cGMP production. The drug preserves the signal but does not generate it.

Accumulated cGMP activates Protein Kinase G (PKG), triggering an intracellular cascade that lowers free calcium ion ( Ca^2+) concentrations. This change causes the relaxation and widening of the smooth muscle walls (vasodilation) in arterioles. The final physiological consequence of this mechanism is the decrease in local vascular resistance and a resulting increase in localized blood perfusion into the affected tissues.

Dosage and Administration Information

Megafil (Tadalafil) is strictly an oral administration medication, supplied as a film-coated tablet. The standard instruction is that the tablet must be swallowed whole and should not be crushed or split before intake. The medication may be taken with or without food, offering flexibility for daily scheduling.

The established usage protocols define two main patterns for administration: Once Daily and As Needed use. For continuous treatment of BPH or Erectile Dysfunction (ED), the dose typically ranges from 2.5 mg to 5 mg, and the instruction is to take it at approximately the same time each day. The As Needed regimen for ED starts at 10 mg and can be adjusted up to a maximum of 20 mg, but administration is limited to not more than once per day.

Usage for Pulmonary Arterial Hypertension (PAH) requires a specific fixed dose of 40 mg once daily, which instructions specify must not be divided into smaller doses across the day. The overall protocol mandates that the dose frequency must not exceed once in a 24-hour period across all approved indications. Furthermore, prescribing information includes dose reductions for patients with specified levels of renal or hepatic impairment, and when the drug is used concurrently with strong enzyme inhibitors. These instructions define the standardized approach to using the medicine.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Megafil (Tadalafil)

The research evidence for Megafil is summarized in official documents and peer-reviewed scientific literature. Research provides context but not individual predictions. Findings describe group patterns observed in clinical trials, not personal outcomes.


Evidence for use in Erectile Dysfunction (ED)

The research landscape for Megafil in the context of Erectile Dysfunction includes numerous short-term randomized controlled trials (RCTs). These studies were used in research exploring how scores change over time by comparing measurements in patients receiving Megafil against those receiving a placebo.

Research has explored measurements related to patient-reported experiences, specifically using validated questionnaires like the IIEF-EF. Studies included a broad population of adult men, including specific subgroups with common comorbidities such as diabetes mellitus and hypertension. Findings describe patterns observed in the studies, which contribute to the broader evidence landscape measured during the study period.

While short-term findings are based on rigorous RCTs, there is limited information for long-term outcomes regarding the maintenance of these reported results over periods exceeding one year.


Evidence for use in Lower Urinary Tract Symptoms (LUTS) associated with BPH

Megafil was studied for use in men experiencing lower urinary tract symptoms associated with Benign Prostatic Hyperplasia (BPH).

Studies focused on patient-reported outcomes describing perceived discomfort related to urination, using the IPSS (International Prostate Symptom Score) to monitor functional limitations. Studies report data show score differences in the Total IPSS score and the related IPSS Quality of Life Index between the Megafil group and the placebo group. However, when studies monitored objective measures such as maximum urinary flow rate (Qmax), data show patterns that were often mixed.

Subgroup findings are uncertain or are not based on large dedicated trials, meaning results apply only to the populations studied in the original research. Data show patterns related to patient-reported outcomes, but objective findings, such as Qmax in BPH, were mixed.


Areas of Research Uncertainty and Gaps

Key limitations exist in the current research, including the lack of information for long-term outcomes, particularly regarding research on the natural progression of BPH over multiple years. Comparative evidence is lacking from head-to-head trials against other therapies.

Key Studies & References

  1. Tadalafil - NIH MedlinePlus
  2. WHO ATC Code G04BE08 Classification
  3. Tadalafil Monograph - StatPearls Publishing (NBK544669)

Frequently Asked Questions (FAQ)

Common questions about Megafil (FAQ)

Q: Is Megafil the same type of medicine as other similar drugs?

Official information describes Megafil as a Phosphodiesterase type 5 (PDE5) inhibitor, placing it within a class that includes other similar medicines. Regulatory documents note that Megafil is known for its prolonged half-life, which is a distinguishing trait among some drugs in this group.

Q: How quickly is Megafil expected to start working?

For its use as needed, official information indicates the medication should be taken prior to sexual activity. Studies show the ability to have sexual activity may be improved for up to 36 hours following a single dose.

Q: How long does the effect of Megafil typically last?

The effect of a single dose, when used as needed, is described in studies as lasting up to 36 hours. This is due to its prolonged half-life, meaning the medication remains present in the system longer than some comparable drugs.

Q: Are there any long-term side effects associated with Megafil use?

Regulatory safety documents list both common, transient side effects and rare, serious adverse events reported during and after clinical trials. Regarding long-term use, the research evidence section notes that there is limited information for outcomes or maintenance of results over periods exceeding one year.

Q: Does Megafil interact with common pain relievers like ibuprofen?

The official interactions list highlights major drug classes that can cause severe reactions, such as nitrates and alpha-blockers. Drug interaction resources compiled from regulatory data generally do not list a clinically significant interaction between Megafil and common nonsteroidal anti-inflammatory drugs (NSAIDs) like ibuprofen.

Q: Are there specific foods or drinks to avoid while using Megafil?

Official prescribing information states that Megafil can be taken with or without food. However, official warnings note that substantial consumption of alcohol (five or more units) may increase the potential for orthostatic signs and symptoms, such as dizziness or lightheadedness upon standing.

Q: Can Megafil affect birth control pills or devices?

Megafil is not indicated for use by women. Official product information contains no regulatory data or clinical findings regarding the medication’s effect on hormonal contraceptives (birth control pills) or contraceptive devices.

Q: Is it normal to feel a change in energy levels when starting Megafil?

Regulatory documents list common side effects such as headache, muscle aches (myalgia), and back pain. Specific changes to energy levels are not typically listed in the tables of most common adverse reactions reported in clinical trials.

Q: Do older adults use a different version or amount of Megafil?

According to official labeling, no dosage adjustment is required solely based on a person's age. However, a dose reduction may be required for any patient, including older adults, who has specific levels of renal or hepatic impairment (kidney or liver issues).

Q: Is Megafil addictive or habit-forming?

Megafil is not physically addictive or habit-forming. Regulatory safety information does not classify the medication as a controlled substance.

Q: Does Megafil have a generic version available yet?

Yes. The active ingredient in Megafil, which is Tadalafil, is widely available in generic versions that have been approved by regulatory bodies.

Q: Does Megafil interact with common supplements like vitamin D?

Official regulatory interaction tables focus on major drug classes and substances like alcohol. Drug interaction checkers, which consolidate safety data, typically do not show a direct interaction between Megafil and common supplements like Vitamin D.

Q: What is the process for deciding if Megafil is right for someone?

The decision requires a healthcare provider's evaluation to determine safety and appropriateness. This assessment focuses on known absolute contraindications (such as taking nitrates) and assessing co-existing health conditions, like a recent heart attack, severe low blood pressure, or severe kidney or liver impairment.

Q: How does Megafil affect blood pressure?

Megafil works by causing vasodilation, which is the widening of blood vessels. It can amplify the effect of other blood pressure-lowering agents and carries an additive risk of symptomatic hypotension (severe blood pressure drops) when used with certain other medicines.

Q: Why do official documents emphasize the importance of using Megafil as described?

Official documents emphasize strict adherence to instructions to ensure both safety and effectiveness. Violating usage protocols, such as exceeding the prescribed frequency, can lead to increased exposure and the potential for dangerous side effects, including severe hypotension.

Q: How is Megafil removed from the body?

Megafil is primarily metabolized by a specific liver enzyme (CYP3A4) for elimination. Regulatory documents state that the majority of the drug is excreted via the feces (about 61% of the dose), with a lesser amount eliminated through the urine.

Q: Can Megafil cause sleep disturbances like insomnia?

Official drug safety documentation lists trouble sleeping (insomnia) as a less common adverse reaction that was reported in some clinical trials. It is not generally listed among the most frequently reported side effects.

Q: Is Megafil a prescription-only medication?

Yes, Megafil is a prescription-only medicine (POM). It is available only with a valid prescription from a licensed healthcare provider, as its use requires a medical evaluation.

Q: What are the possible signs of an interaction between Megafil and another drug?

The most serious sign of a dangerous drug interaction is symptomatic hypotension (severe blood pressure drops), which may include symptoms such as dizziness, fainting, or lightheadedness upon standing. Sudden changes in vision or hearing are also considered serious signs that necessitate medical evaluation.

Q: What should a person know about Megafil before talking to their healthcare provider?

Official patient counseling information discusses key information for a consultation. This commonly includes information regarding cardiovascular health status, all current medications and supplements (especially nitrates), and any history of vision or hearing loss.

Q: What does the term 'contraindication' mean in the context of Megafil?

A contraindication means the medicine is medically prohibited under certain circumstances, as the potential risk significantly outweighs any benefit. For Megafil, absolute contraindications include taking any form of organic nitrate or having an allergy to any of the ingredients.

Q: Can Megafil affect a person's mood or emotional state?

Official regulatory information does not list major mood changes as a common side effect. However, some adverse event reports have included feelings such as discouragement, sadness, or irritability, though these are not listed as frequent reactions.

Q: Does Megafil require any regular monitoring or blood tests?

Regulatory documents note that for patients being treated for Pulmonary Arterial Hypertension (PAH), regular monitoring or tests may be required by the prescribing physician. For other uses, the need for tests is based on the individual patient's underlying health conditions.

Q: How long after stopping Megafil do its effects usually disappear?

Based on the drug's half-life, it takes approximately two days (48 hours) for the drug's concentration in the body to drop to negligible levels. Official guidelines recommend a minimum of 48 hours separation if a patient needs to use nitrate products after their last Megafil dose.

Q: Is it safe to drive or operate machinery after using Megafil?

Official product information notes that dizziness has been reported in clinical trials. Due to this risk, official information notes that activities requiring focus, such as driving or operating machines, should be approached with caution.

Q: Does Megafil affect fertility in men or women?

Studies have shown a decrease in sperm concentration in some men. However, official information states it is currently unknown whether this observed decrease is actually associated with effects on male fertility.

Q: Are there common reasons why a doctor might discontinue Megafil use?

Regulatory documents describe certain serious adverse events, such as a prolonged erection (priapism) lasting four hours or longer, or a sudden loss of vision/hearing, that necessitate discontinuing the use of Megafil.

Q: Can Megafil cause changes to appetite or weight?

Regulatory documents generally do not list weight change as a common side effect. However, loss of appetite has been reported in adverse event reports, though the frequency of this reaction is not known.

How should Megafil be stored and disposed of?

How to Store and Dispose of Megafil (Tadalafil)

The storage and disposal of Megafil tablets must adhere strictly to official regulatory guidelines to preserve stability and ensure safety.

Storage Requirement Official Condition
Temperature Store no higher than 30 C (86 F), away from excessive heat.
Protection Keep in the original package to protect the medicine from moisture and light.
Child Safety Must be stored out of the sight and reach of children.

Disposal

Expired or unused tablets must be disposed of according to local requirements. Megafil is not on the list of medicines recommended for flushing. The preferred method is a drug take-back program. If this is unavailable, discard the tablets in the household trash by mixing them with an undesirable substance, sealing the mixture in a container, and removing all personal information from the label.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Megafil found in:

A-Z Index: